Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Astrazeneca Plc ADR (NQ: AZN )

65.63 +1.37 (+2.13%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc ADR

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
59 60 Next >
Should Quality-Oriented Investors Explore ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN)?
Why Quality-Oriented Investors Should Consider NASDAQ:AZN. 
Via Chartmill
European Stock: AstraZeneca
AstraZeneca PLC is a science-led biopharmaceutical company. The company focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and... 
Via Talk Markets
Looking At AstraZeneca's Recent Unusual Options Activity
Via Benzinga
Brexit Impact On Drugs - Rising Shortages in UK Highlight Brexit Challenges
Discover the impact of Brexit on UK drug shortages. Insights from a recent Nuffield Trust study reveal a doubling in shortages since 2020. Learn about challenges in medicine supplies, regulatory... 
Via Benzinga
Topics Brexit
Exposures Brexit
3 Blue-Chip Stocks to Buy as High Inflation Persists
These are the undervalued blue-chip stocks for inflation protection, with the Fed likely to delay the first interest rate cut. 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
Via AB Newswire
Topics Economy
Exposures Interest Rates
A Closer Look at AstraZeneca's Options Market Dynamics
Via Benzinga
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Corporate profit growth rose in Q3 2023 and is expected to continue in Q1. 
Via Benzinga
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
Amgen's Tezspire shows promising COPD trial results and potential market expansion beyond asthma. Comparison with Dupixent reveals significant benefits for eosinophil counts ≥150 cells/μL and ≥300... 
Via Benzinga
AstraZeneca's Imfinzi/Chemo Combo Doubles Overall Survival In Biliary Tract Cancer Patients At 3 Years, Data Shows
AstraZeneca's updated data from TOPAZ-1 Phase 3 trial of Imfinzi (durvalumab) in advanced biliary tract cancer patients. Unveiling long-term survival benefits and significant overall survival... 
Via Benzinga
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
From AstraZeneca
Via Business Wire
3 Pharma Stocks That Are Money-Printing Machines in 2024
The economy, and pharma industry, are projected to grow massively. You should invest in these top three pharma stocks. 
Via InvestorPlace
Topics Economy
Exposures Economy
4 Exceptional Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
Amazing deals can still be found by opportunistic investors, even with the Nasdaq Composite reaching new heights. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee found no conclusive evidence linking GLP-1 receptor agonists to suicidal or self-injurious thoughts. Following thorough... 
Via Benzinga
Exposures Product Safety
Biotech Innovations Paving the Way in Breast Cancer Fight
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:GTHX),(NASDAQ:AZN),(NASDAQ:HOLX) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Exposures Death Product Safety
AstraZeneca Hikes Annual Dividend By 7% Just Before Vote On Its CEO's Pay Package Boost
AstraZeneca boosts its 2024 dividend to $3.10/share, reflecting confidence in performance. Shareholder concerns addressed as CEO compensation proposal approaches vote. Recent acquisitions and FDA... 
Via Benzinga
Exposures Product Safety
FASENRA approved for treatment of children aged 6 to 11 with severe asthma
From AstraZeneca
Via Business Wire
AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
FDA approves Daiichi Sankyo's and AstraZeneca's Enhertu for unresectable or metastatic HER2+ solid tumors. Accelerated approval based on ORR and DOR. Boxed warnings for ILD/pneumonitis and embryo-fetal... 
Via Benzinga
Exposures Product Safety
US Manufacturing Hits 18-Month High, China's Growth Could Trigger Deflation And More: Economics Weekly Roundup
This week's top stories highlight significant developments, including the U.S. manufacturing sector reaching an 18-month high, potential deflation from China's manufacturing growth, a robust U.S. labor... 
Via Benzinga
Topics Economy
Exposures Interest Rates
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
From Daiichi Sankyo
Via Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors
From AstraZeneca
Via Business Wire
New Hope for Aggressive Lung Cancer: AstraZeneca's Imfinzi Shows Promising Results in Phase 3 Trial
High-level results of AstraZeneca's ADRIATIC Phase 3 trial on Imfinzi monotherapy & Imfinzi plus Imjudo for limited-stage small cell lung cancer. Statistically significant OS & PFS improvement shown... 
Via Benzinga
IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial
From AstraZeneca
Via Business Wire
AstraZeneca CEO Highlights Decade-Long Sales Goal Of $45B Along With Investor Doubts As It Lags In Weight Loss Race
AstraZeneca's CEO Pascal Soriot celebrates hitting a $45 billion sales target set a decade ago despite initial skepticism. Investor confidence remains a challenge amid stagnant shares and concerns over... 
Via Benzinga
Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
From AstraZeneca
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AdTheorent Holding Company, Inc. (Nasdaq – ADTH), Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN)
From Brodsky & Smith LLC
Via GlobeNewswire
VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH
From Alexion
Via Business Wire
7 Blue-Chip Stocks That Will Outperform the Dow in the 5 Five Years
These are the blue-chip stocks to outperform Dow in the next five years and represents companies with growth and cash flow visibility. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Bull Market Buys: 3 Dividend Stocks to Own for the Long Run
Invest in stability, dividends, and growth with these three accomplished real estate operators. 
Via The Motley Fool
What's Going On European Pharma Giant AstraZeneca Stock On Wednesday?
Japan approves AstraZeneca & Sanofi's Beyfortus for respiratory syncytial virus in neonates, infants, & children. Also, Truqap receives approval for unresectable or recurrent breast cancer. AstraZeneca... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
59 60 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.